The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 15 of the 26 sources its claims cite were checked for support.
Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Open accessAbstract
This phase 2 randomized placebo-controlled trial included parallel cohorts of patients with IPF and PPF treated with admilparant 30 mg, 60 mg, or placebo for 26 weeks; the 60 mg dose showed numerically better preservation of ppFVC, especially in PPF.
Overview
CoChat Summary
TL;DR
This phase 2 randomized, double-blind, placebo-controlled trial found that 60 mg twice daily of admilparant, an oral LPA1 antagonist, slowed 26-week lung function decline in both IPF and PPF cohorts. The drug was generally safe and well tolerated, with diarrhea and transient blood pressure reductions being the main safety signals.
Key findings
- In the IPF cohort, the 26-week rate of change in ppFVC was -2.7% with placebo, -2.8% with 30 mg, and -1.2% with 60 mg; the 60 mg vs placebo treatment difference was 1.4% (95% CI, -0.1 to 3.0) under the treatment-policy estimand and 1.8% (95% CI, 0.2 to 3.4) under the while-on-treatment estimand.
- In the PPF cohort, the 26-week rate of change in ppFVC was -4.3% with placebo, -2.9% with 30 mg, and -1.1% with 60 mg; the 60 mg vs placebo treatment difference was 3.2% (95% CI, 0.7 to 5.7) under the treatment-policy estimand and 3.0% (95% CI, 0.4 to 5.6) under the while-on-treatment estimand.
- Bayesian analysis in the IPF cohort gave a posterior probability of >95% for a positive treatment difference for 60 mg admilparant vs placebo under both estimand strategies.
- Safety was broadly comparable across arms: TEAEs occurred in 80%/76%/74% of IPF patients and 78%/83%/67% of PPF patients in placebo/30 mg/60 mg arms, respectively; serious TEAEs and discontinuations were generally lower with admilparant than placebo, especially in PPF (discontinuations 17% placebo vs 3% and 0% with 30 mg and 60 mg).
Methods
- Phase 2, randomized, double-blind, placebo-controlled trial with parallel IPF and PPF cohorts at 79 sites in 17 countries; 1:1:1 randomization to 30 mg admilparant, 60 mg admilparant, or placebo twice daily for 26 weeks.
- Sample: 403 randomized (278 IPF, 125 PPF); 399 treated (276 IPF, 123 PPF). Background antifibrotics were allowed in both cohorts, and ILD-targeted immunosuppressants were allowed in PPF.
- Primary endpoint was change in percentage of predicted FVC (ppFVC) from baseline to week 26; analyses used linear mixed-effects models, a two-estimand framework (treatment-policy and while-on-treatment), and a Bayesian supportive analysis for the IPF cohort.
Limitations
- The paper states that the study was not powered to claim statistical significance, and results are estimation-based.
- The 26-week duration was not sufficient to determine whether FVC effects translate into long-term outcomes such as quality of life or hospitalizations; the authors say larger and longer trials are needed.
- The small number of patients not on background antifibrotics limited firm subgroup conclusions; this is stated in the paper.
- Evident from the text: PPF was heterogeneous and the cohort excluded connective tissue disease ILD other than rheumatoid arthritis-associated ILD, so generalizability to other immune-mediated ILDs is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 2 Not valid · 4 Not checked · 73 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“current anti fi brotic therapies, which were used as background treatment in 67% and 37% of the IPF and PPF cohorts in this study, respectively, are associated with gastrointestinal adverse effects (2, 3)”
What the sources say
- Could not verifycites [2] Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med sourceExperimental — accuracy not yet measured
The passages available from our copy contain only the paper’s title, author metadata, and repository navigation text; none reports adverse effects. Searches for gastrointestinal effects, diarrhea, and safety findings returned no relevant passage, so the attributed claim cannot be verified from this copy. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [3] King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and in four patients (3%) with PPF (placebo: n =3; 60 mg: n =1).”
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment difference between the 60-mg admilparant arm versus placebo was 1.8% (95% CI, 0.2 to 3.4), a 62% relative reduction (Figure 1B).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and in 78% (placebo), 83% (30 mg), and 67% (60 mg) in the PPF cohort”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment differences in rates of change in ppFVC were consistent with or without background anti fi brotic use in both the IPF (Figures 3A and 3B) and PPF cohorts (Figures 3C and 3D).”
- Also stated in: § Discussion · plain
“The treatment effect of 60 mg of admilparant was consistent in subgroups of patients with and without background anti fi brotic use in both cohorts and in the presence and absence of UIP pattern in the PPF cohort.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
38 more claims
Create a free account to see all 90 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 21
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 2
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationRaghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationTager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Self-citationBehr, J., Prasse, A., Kreuter, M., Johow, J., Rabe, K. F., Bonella, F., Bonnet, R., Grohe, C., Held, M., Wilkens, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30554-3 · Cited by 522
Self-citationPalmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
Cited by
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 149
Self-citationFerroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities
Yao, M., Liu, Z., Zhao, W., Song, S., Huang, X., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567994 · Cited by 59
Nadhan, R., Nath, K., Basu, S., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02423-4 · Cited by 39
Emerging therapies for the treatment of systemic sclerosis
Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 29
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Metadata
- Authors
- Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., Elpers, B., Kim, S., Watanabe, H., Fischer, A., & Maher, T. M.
- Affiliations
- The University of Sydney (AU)
- Department of Medicine V, LMU University Hospital, LMU Munich, Member of the German Center for Lung Research, Munich, Germany
- Hospices Civils de Lyon (FR)
- Loyola University Chicago (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York
- Kanagawa Cardiovascular and Respiratory Center (JP)
- Hamamatsu University (JP)
- Erasmus MC (NL)
- Bristol-Myers Squibb (United States) (US)
- University of Southern California (US)
- Corresponding author
- Maher, Toby M.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-02-01
- Volume
- 211
- Issue
- 2
- Pages
- 230-238
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W4403320879
- Cited by
- 70
- References
- 16
- Citations by year
- 2026: 40 · 2025: 28
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- Bristol Myers Squibb
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, lung function, drug safety, diarrhea, hypotension, adverse events, dose comparison, immunosuppressants
- MeSH terms
- Antifibrotic Agents, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pulmonary Fibrosis, Vital Capacity, Treatment Outcome, Receptors, Lysophosphatidic Acid, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.202405-0977oc
- The paper
- Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., Elpers, B., Kim, S., Watanabe, H., Fischer, A., & Maher, T. M. (2025). Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202405-0977oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.